• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于定量载脂蛋白CII和CIII的免疫比浊技术。

Immunoturbidimetric techniques for quantifying apolipoproteins CII and CIII.

作者信息

Rifai N, Silverman L M

出版信息

Clin Chem. 1986 Oct;32(10):1969-72.

PMID:3093121
Abstract

Immunoturbidimetric assays for determination of serum apolipoproteins CII and CIII (apo CII and CIII) were developed for use on the Cobas-Bio centrifugal analyzer with commercially available antisera and reference sera. Within-run and between-run imprecision (CVs) for apo CII was respectively 3.3 and 6.2%, and for apo CIII 2.75 and 5.2%. Addition to sera of as much as 50 g of hemoglobin or 0.15 g of bilirubin per liter did not interfere with determinations of apolipoproteins. Concentrations of apo CII and CIII were measured in sera from 40 normolipidemic and hyperlipidemic subjects by these immunoturbidimetric methods (x) and by radial immunodiffusion assays (y). Apo CII and CIII gave slopes of 0.93 and 0.86, y-intercepts of 7.4 and 9.5 mg/L, and correlation coefficients of 0.96 and 0.94, respectively. Reference intervals for the two apolipoproteins were established with sera from 100 normolipidemic subjects. The distribution of apo CII and CIII among the various lipoprotein fractions for normal subjects differed significantly (p less than 0.005) from that for hypertriglyceridemic subjects.

摘要

采用市售抗血清和参考血清,开发了用于在Cobas-Bio离心分析仪上测定血清载脂蛋白CII和CIII(apo CII和CIII)的免疫比浊法。apo CII的批内和批间不精密度(CV)分别为3.3%和6.2%,apo CIII的批内和批间不精密度分别为2.75%和5.2%。每升血清中加入多达50 g血红蛋白或0.15 g胆红素不会干扰载脂蛋白的测定。通过这些免疫比浊法(x)和放射免疫扩散法(y)测量了40名血脂正常和血脂异常受试者血清中apo CII和CIII的浓度。apo CII和CIII的斜率分别为0.93和0.86,截距分别为7.4和9.5 mg/L,相关系数分别为0.96和0.94。用100名血脂正常受试者的血清建立了这两种载脂蛋白的参考区间。正常受试者和高甘油三酯血症受试者各种脂蛋白组分中apo CII和CIII的分布差异显著(p小于0.005)。

相似文献

1
Immunoturbidimetric techniques for quantifying apolipoproteins CII and CIII.用于定量载脂蛋白CII和CIII的免疫比浊技术。
Clin Chem. 1986 Oct;32(10):1969-72.
2
A simple immunotechnique for the determination of serum concentration of apolipoprotein E.一种用于测定血清载脂蛋白E浓度的简易免疫技术。
Clin Chim Acta. 1987 Mar 16;163(2):207-13. doi: 10.1016/0009-8981(87)90024-6.
3
Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radial immunodiffusion assays.
J Clin Lab Anal. 1991;5(2):90-5. doi: 10.1002/jcla.1860050204.
4
Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum.
Clin Chem. 1986 Jun;32(6):957-61.
5
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.2型糖尿病患者极低密度脂蛋白亚类中脂质和载脂蛋白CIII的改变
Diabetologia. 2005 Jun;48(6):1207-15. doi: 10.1007/s00125-005-1753-z. Epub 2005 Apr 30.
6
Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients.
Clin Chem. 1991 Mar;37(3):387-93.
7
Determination of apolipoprotein B in apolipoprotein CII/CIII-containing lipoproteins by an immunoenzymmetric assay.采用免疫酶法测定含载脂蛋白CII/CIII的脂蛋白中的载脂蛋白B。
Eur J Clin Chem Clin Biochem. 1992 Apr;30(4):223-8. doi: 10.1515/cclm.1992.30.4.223.
8
Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment.在接受慢性血液透析治疗的正常甘油三酯血症和高甘油三酯血症患者中,均可能出现极低密度脂蛋白载脂蛋白CII/载脂蛋白CIII比值降低的情况。
Metabolism. 1987 Sep;36(9):815-20. doi: 10.1016/0026-0495(87)90087-4.
9
[The ratios of apoC-III/apoC-II in normal full-term maternal bloods and their umbilical cord bloods].
Rinsho Byori. 2001 Jan;49(1):45-50.
10
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.外源性脂质及载脂蛋白CI、CII、CIII和E对脂蛋白B与低密度脂蛋白受体结合的调节作用。
Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):963-71. doi: 10.1161/01.atv.15.7.963.

引用本文的文献

1
Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?为何载脂蛋白CIII正成为减轻心血管疾病负担的新型治疗靶点?
Curr Atheroscler Rep. 2016 Oct;18(10):59. doi: 10.1007/s11883-016-0614-1.
2
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.血栓形成倾向因素并非白塞病血栓形成的主要原因。
Ann Rheum Dis. 2004 Nov;63(11):1445-9. doi: 10.1136/ard.2003.014241.